Showing 721-730 of 3082 results for "".
Filling the Gaps in the Multiple Sclerosis Treatment Landscape
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/filling-the-gaps-in-the-multiple-sclerosis-treatment-landscape/30372/The addition of a potential breakthrough agent may change the treatment arena, but wellness and early treatment remain the foundation of effective care.Stroke Busters: Mobile Stroke Units Offer a New Approach to Care
https://practicalneurology.com/diseases-diagnoses/imaging-testing/stroke-busters-mobile-stroke-units-offer-a-new-approach-to-care/30593/Calling 911 in Cleveland might deliver a highly specialized vehicle to suspected stroke patients. What's behind the new intervention?NEWS
https://practicalneurology.com/columns/practice-management/news/30702/News
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/news/30253/Lawful Physician-Hastened Death, Hearing Loss and Cognitive Impairment, Extended-Release Amantadine, Fibromyalgia Biomarkers, Phase 3 Trial of Rimegepant for Migraine, A Blood Test for Concussion, and more.Multiple Sclerosis Minute: Novel Treatment Options for Neuromyelitis Optica Spectrum Disorder
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/multiple-sclerosis-minute-novel-treatment-options-for-neuromyelitis-opticaspectrum-disorder/31844/Relapse prevention is critical for preventing the accumulation of disability in NMOSD and new monoclonal antibody therapies are highly effective at doing so.Update in Epilepsy Therapeutics
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/update-in-epilepsy-therapeutics/30511/In addition to comorbid conditions and side effects, cost and availability should factor into therapeutic selection.Opportunities for Patients Arising From Practicalities of Health Care
https://practicalneurology.com/archives/2018-feb/opportunities-for-patients-arising-from-practicalities-of-health-care/30273/Telepresence in Neurology
https://practicalneurology.com/columns/practice-management/telepresence-in-neurology/30389/Delayed MS Drugs Awaits Decision at FDA
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/delayed-ms-drugs-awaits-decision-at-fda/30657/Pain and Gain: Reassessing Hydrocodone Prescribing
https://practicalneurology.com/diseases-diagnoses/headache-pain/pain-and-gain-reassessing-hydrocodone-prescribing/30742/New recommendations by an FDA committee aim to decrease opioid abuse, the group says, but will physicians and patients bear the burden of its effects?